原发性肝癌中西医结合介入诊疗专家共识(试行第一版)

2021-11-20 2019 年肝癌中西医临床协作专家委员会 介入放射学杂志

本共识由国家中医药管理局重大疑难疾病-中西医临床协作项目-肝癌项目组牵头撰写。

中文标题:

原发性肝癌中西医结合介入诊疗专家共识(试行第一版)

发布日期:

2021-11-20

简要介绍:

本共识由国家中医药管理局重大疑难疾病-中西医临床协作项目-肝癌项目组牵头撰写,该项目建立了早期肝癌微创根治性消融和中晚期肝癌TAE/TACE序贯微创介入消融,联合中医辨证整体施治,形成了介入栓塞标记肿瘤,序贯微创局部消融及解剖模式消融术,去除影像学可见肿瘤,建立了以肝段消融术为代表的肝脏消融体系;应用中医扶正去邪提升机体免疫功能,重塑不适合肿瘤生长的微环境,去除影像学不可见的微小肿瘤,探索出了“中西医结合临床协作治疗肝癌”的整体解决方案。

相关资料下载:
[AttachmentFileName(sort=1, fileName=原发性肝癌中西医结合介入诊疗专家共识(试行第一版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=77c3f1c0022e1ace, title=原发性肝癌中西医结合介入诊疗专家共识(试行第一版), enTitle=, guiderFrom=介入放射学杂志, authorId=0, author=, summary=本共识由国家中医药管理局重大疑难疾病-中西医临床协作项目-肝癌项目组牵头撰写。, cover=https://img.medsci.cn/20211125/1637833337542_5579292.png, journalId=0, articlesId=null, associationId=2152, associationName=2019 年肝癌中西医临床协作专家委员会, associationIntro=2019 年肝癌中西医临床协作专家委员会, copyright=0, guiderPublishedTime=Sat Nov 20 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">本共识由国家中医药管理局重大疑难疾病-中西医临床协作项目-肝癌项目组牵头撰写,该项目建立了早期肝癌微创根治性消融和中晚期肝癌TAE/TACE序贯微创介入消融,联合中医辨证整体施治,形成了介入栓塞标记肿瘤,序贯微创局部消融及解剖模式消融术,去除影像学可见肿瘤,建立了以肝段消融术为代表的肝脏消融体系;应用中医扶正去邪提升机体免疫功能,重塑不适合肿瘤生长的微环境,去除影像学不可见的微小肿瘤,探索出了&ldquo;中西医结合临床协作治疗肝癌&rdquo;的整体解决方案。</span></p>, tagList=[TagDto(tagId=439, tagName=消化道肿瘤), TagDto(tagId=1097, tagName=原发性肝癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=22, categoryName=肝病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=91, categoryName=肝胆胰外, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1097, guiderKeyword=原发性肝癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3874, appHits=101, showAppHits=0, pcHits=455, showPcHits=3773, likes=0, shares=13, comments=9, approvalStatus=1, publishedTime=Thu Nov 25 17:54:34 CST 2021, publishedTimeString=2021-11-20, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Thu Nov 25 17:46:10 CST 2021, updatedBy=6415643, updatedName=凯晨, updatedTime=Fri Jan 05 05:40:46 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=原发性肝癌中西医结合介入诊疗专家共识(试行第一版).pdf)])
原发性肝癌中西医结合介入诊疗专家共识(试行第一版).pdf
下载请点击:
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1207086, encodeId=8da7120e0862e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:43:49 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074951, encodeId=d0c510e49511d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Mon Nov 29 07:00:03 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074507, encodeId=623810e450737, content=肝癌发病者还是较多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78db5723254, createdName=ms2000000637474384, createdTime=Sat Nov 27 14:54:23 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074506, encodeId=70a410e45067d, content=好好学, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78db5723254, createdName=ms2000000637474384, createdTime=Sat Nov 27 14:53:08 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074394, encodeId=41fa10e439413, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Nov 27 06:57:42 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2022-03-30 56446_2968

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1207086, encodeId=8da7120e0862e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:43:49 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074951, encodeId=d0c510e49511d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Mon Nov 29 07:00:03 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074507, encodeId=623810e450737, content=肝癌发病者还是较多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78db5723254, createdName=ms2000000637474384, createdTime=Sat Nov 27 14:54:23 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074506, encodeId=70a410e45067d, content=好好学, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78db5723254, createdName=ms2000000637474384, createdTime=Sat Nov 27 14:53:08 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074394, encodeId=41fa10e439413, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Nov 27 06:57:42 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2021-11-29 微探

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1207086, encodeId=8da7120e0862e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:43:49 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074951, encodeId=d0c510e49511d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Mon Nov 29 07:00:03 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074507, encodeId=623810e450737, content=肝癌发病者还是较多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78db5723254, createdName=ms2000000637474384, createdTime=Sat Nov 27 14:54:23 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074506, encodeId=70a410e45067d, content=好好学, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78db5723254, createdName=ms2000000637474384, createdTime=Sat Nov 27 14:53:08 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074394, encodeId=41fa10e439413, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Nov 27 06:57:42 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2021-11-27 ms2000000637474384

    肝癌发病者还是较多

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1207086, encodeId=8da7120e0862e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:43:49 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074951, encodeId=d0c510e49511d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Mon Nov 29 07:00:03 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074507, encodeId=623810e450737, content=肝癌发病者还是较多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78db5723254, createdName=ms2000000637474384, createdTime=Sat Nov 27 14:54:23 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074506, encodeId=70a410e45067d, content=好好学, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78db5723254, createdName=ms2000000637474384, createdTime=Sat Nov 27 14:53:08 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074394, encodeId=41fa10e439413, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Nov 27 06:57:42 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2021-11-27 ms2000000637474384

    好好学

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1207086, encodeId=8da7120e0862e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:43:49 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074951, encodeId=d0c510e49511d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Mon Nov 29 07:00:03 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074507, encodeId=623810e450737, content=肝癌发病者还是较多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78db5723254, createdName=ms2000000637474384, createdTime=Sat Nov 27 14:54:23 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074506, encodeId=70a410e45067d, content=好好学, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78db5723254, createdName=ms2000000637474384, createdTime=Sat Nov 27 14:53:08 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074394, encodeId=41fa10e439413, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Nov 27 06:57:42 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2021-11-27 微探

    学习学习

    0

拓展阅读

2016 注射用洛铂在原发性肝癌TACE 治疗中的专家共识

中国医师协会介入医师分会 · 2016-09-30

2016年原发性肝癌放疗共识

暂未更新 · 2016-11-30

《原发性肝癌规范化病理诊断指南(2015 年版)》解读

中国抗癌协会肝癌专业委员会(CSLC,Chinese Society of Liver Cancer) · 2016-07-30